VIDEO: Yutiq, Dexycu trial data positive

SAN FRANCISCO — At the Ophthalmology Innovation Summit preceding the American Academy of Ophthalmology annual meeting, Nancy Lurker, CEO of EyePoint Pharmaceuticals, discusses new data the company is presenting at the AAO on its products Yutiq (fluocinolone acetonide intravitreal implant 0.18 mg) and Dexycu (dexamethasone intraocular suspension 9%).

Full Story →